FGEN FibroGen, Inc

26.30
+1  (2%)
Previous Close 25.75
Open 25.90
Price To book 10.52
Market Cap 1.68B
Shares 63,888,000
Volume 307,335
Short Ratio 6.49
Av. Daily Volume 484,481

SEC filingsSee all SEC filings

  1. 8-K - Current report 17746681
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17746663
  3. 8-K - Current report 17727955
  4. CT ORDER - Confidential treatment order 17674483
  5. 8-K - Current report 17659441

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 3Q 2017.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 3 data from China trial released January 30, 2017. Primary endpoints met.
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 2 data due 3Q 2017.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
Pamrevlumab (FG-3019)
Pancreatic cancer

Latest News

  1. Why FibroGen Inc Popped Higher Today
  2. Traders Are Focused on the Big-Caps
  3. FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
  4. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 4, 2017
  5. FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
  6. Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
  7. FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  8. Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT
  9. FibroGen Reports Fiscal 2016 Financial Results
  10. FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017
  11. FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
  12. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017
  13. Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
  14. Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
  15. FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
  16. FibroGen (FGEN) Shares March Higher, Can It Continue?
  17. Here Are Two Market Moving Biotech Catalysts To Watch This Week
  18. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  19. Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.